Article

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

2023-06-13

Abstract excerpt

Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this therapeutic approach remains controversial in selected NSCLC subsets, such as those of the elderly with active brain m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d8ef61f7-a3e5-56a2-a4d7-be511c1f821e
DOI: 10.20944/preprints202306.0956.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?DOI 10.20944/preprints202306.0956.v1Read

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity Read

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.Semantic proximity Read

Non–Small Cell Lung Cancer Metastatic Without Oncogenic AlterationsSemantic proximity Read

Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.Semantic proximity Read

[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].Semantic proximity Read

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read